{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:09:16Z","timestamp":1783933756929,"version":"3.55.0"},"reference-count":0,"publisher":"Dustri-Verlag Dr. Karl Feistle","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CP"],"published-print":{"date-parts":[[2026,8,1]]},"DOI":"10.5414\/cp204964","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:03:54Z","timestamp":1778501034000},"page":"407-415","source":"Crossref","is-referenced-by-count":0,"title":["Evolocumab, a proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitor, is effective and safe in the treatment of hyperlipidemia in chronic kidney disease stage 3 \u2013 4"],"prefix":"10.5414","volume":"64","author":[{"given":"Hongxu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3374","container-title":["Int. Journal of Clinical Pharmacology and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:44:13Z","timestamp":1783932253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dustri.com\/article_response_page.html?artId=192917&doi=10.5414\/CP204964&L=0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":0,"journal-issue":{"issue":"08","published-print":{"date-parts":[[2026]]}},"alternative-id":["204964"],"URL":"https:\/\/doi.org\/10.5414\/cp204964","relation":{},"ISSN":["0946-1965"],"issn-type":[{"value":"0946-1965","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}